| Name | Title | Contact Details |
|---|---|---|
Gregory Flesher |
President and Chief Executive Officer | Profile |
Jennifer Lam |
VP of Finance and Administration | Profile |
Cutanix Corporation is a Franksville, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Colorado Choice Health Plan is a Alamosa, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmaceutical Services Corp is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.
EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.